Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.37 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30859432 | 0.99 | MME (0.40) | MMEENPEPGNPATPLA2G2ACASP3 | |
| SCHEMBL30798035 | 0.98 | MME (0.41) | MMEENPEPGNPATPLA2G2ACASP3 | |
| SCHEMBL29510840 | 0.96 | MME (0.38) | MMEENPEPGNPAT | |
| SCHEMBL29360643 | 0.95 | MME (0.42) | MMEENPEPGNPATCASP3ECE1 | |
| SCHEMBL30477912 | 0.94 | MME (0.40) | MMEENPEPGNPATPLA2G2ACASP3 | |
| SCHEMBL31707374 | 0.93 | MME (0.38) | MMEENPEPGNPATOPRD1ECE1 | |
| SCHEMBL30477909 | 0.93 | MME (0.37) | MMEENPEPGNPATCASP3CASP7 | |
| SCHEMBL29598237 | 0.92 | MME (0.40) | MMEENPEPGNPATCA2CA1 | |
| SCHEMBL31310661 | 0.92 | MME (0.38) | MMEENPEPGNPAT | |
| SCHEMBL10856404 | 0.92 | SLC15A2 (0.35) | MMESLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| US-20240390478-A1 | VACCINATION IN ELDERLY PATIENTS | CureVac SE (DE) | 2024-11-28 | — | — | US | disclosed |
| US-12036277-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240197857-A1 | VACCINATION WITH mRNA-CODED ANTIGENS | CureVac SE (DE) | 2024-06-20 | — | — | US | disclosed |
| US-11975064-B2 | Vaccination with mRNA-coded antigens | CureVac SE (DE) | 2024-05-07 | — | — | US | disclosed |
| US-20230285594-A1 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION | CureVac SE (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230233662-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2023-07-27 | — | — | US | disclosed |
| US-11672856-B2 | Vaccination in newborns and infants | CureVac SE (DE) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | MME 2664/4885ENPEP 910/4885GNPAT 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.